

# Max Healthcare Institute | ADD

## In-line 2Q; CGHS boost to margin in horizon

Max Healthcare delivered a strong 2QFY26 with revenue/EBITDA/PAT growing 21%/23%/59% YoY. The performance was broadly in line at the top-line and ahead on profitability, aided by a favourable tax impact of INR 1.5bn (ex-one-off +16% YoY). The growth was supported by the existing hospitals, which posted +14% YoY revenue and +19% YoY EBITDA growth. The existing hospitals' performance was on the back of an 11% increase in operating beds and a 3% improvement in ARPOB. The new units contributed INR 1.4bn in revenue and INR 230mn in EBITDA. ARPOB grew 1.4% YoY (7% on like-to-like basis), occupancy stood at a healthy 77% (existing units >79%), and EBITDA per bed improved to INR 7.3mn. International contribution increased to 9.2%, with ARPOB ~50% higher than domestic patients. The CGHS price revision is expected to contribute ~INR 2bn annually to revenue, with 85–90% EBITDA flow-through, to be fully realised FY27 onwards. Labs/Home businesses continued to scale, reporting 18%/20% YoY growth. Operationally, Mohali's 160-bed brownfield tower is commissioned, Nanavati's 268-bed expansion goes live shortly, and the larger 400-bed Mohali expansion is progressing ahead of schedule. With strong operating momentum, improving payer mix, and multi-site expansion visibility, we remain constructive on Max's growth outlook and margin trajectory. We value the stock using SOTP methodology to arrive at a TP of INR 1,181; rating the stock as ADD, in-line with our new rating system.

- Key metrics:** The new units contributed INR 1.4bn in revenue, with existing units witnessing YoY revenue growth of 14% and EBITDA growth of 19%. The YoY growth was mainly driven by increase in operating beds of 11% and 3% in ARPOB. Share of revenue for International patients increased to 9.2% (vs. 8.9% in 2QFY25). ARPOB for international patients is typically 50% higher. New units contributed INR 230mn in EBITDA. EBITDA margin for existing units stood at 27.5%. EBITDA per bed stood at INR 7.3mn (vs. INR 7.1mn in 2QFY25). Overall occupancy was 77% (vs. 79% in 2QFY25), with existing units occupancy levels 79%. ARPOB was up by 1.4% YoY, subdued on account of new units. On a like-to-like basis, ARPOB growth was 7%. ALOS was down by 2.4% YoY. PAT included favourable tax impact of INR 1.5bn arising from CRL and JHL merger. Excluding this one-off, PAT stood at INR 4.1bn (+16% YoY).
- CGHS revision:** CGHS stands at ~10% of overall payor mix. Management anticipates ~INR 2bn positive impact on top-line on account of recent CGHS rate revision and like-accounts price revision, once fully implemented. Some of it has started to materialise, remaining will come in post full enforcement. Can expect full contribution in FY27, with 85–90% EBITDA flow-through.
- Labs and home:** Max Labs reported strong double-digit growth of 18% YoY in Gross Billing Value and 16% YoY in net revenue to INR 540mn in 2QFY26. The lab services are now available across 60+ cities, offering over 2,700+ tests. Max Home's revenue increased by 20% YoY to INR 630mn; driven by physio & rehab, critical care (Assistance Services), medicine delivery (Transactional Services) and medical room.
- Recent brownfield completions and corporate updates:** The integration of newly acquired Noida (Jaypee Hospital) is nearly complete. The company has commissioned brownfield tower Mohali unit with a capacity of 160 beds (including the additional radiation oncology program). The Nanavati unit (Mumbai) 268 beds brownfield expansion is to be commissioned in coming week. Jaypee Healthcare has divested its hospitals in Chittan and Anoopshahr, effective 18th September 2025, enabling sharpened focus on super specialty care in larger cities. The 400 bed Mohali expansion is continuing faster than anticipated, expected to be completed by CY27 end.

Financial Summary						(INR mn)
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E	
Net Sales	68,150	86,210	1,03,611	1,34,637	1,60,286	
Sales Growth (%)	16.0	26.5	20.2	29.9	19.1	
EBITDA	18,730	22,730	27,146	36,083	42,315	
EBITDA Margin (%)	27.5	26.4	26.2	26.8	26.4	
Adjusted Net Profit	12,790	14,578	18,023	24,251	29,436	
Diluted EPS (INR)	13.2	15.0	18.5	25.0	30.3	
Diluted EPS Growth (%)	17.6	14.0	23.6	34.6	21.4	
ROIC (%)	15.1	13.5	14.5	17.5	19.7	
ROE (%)	14.7	14.7	15.9	18.3	18.9	
P/E (x)	85.3	74.8	60.5	45.0	37.0	
P/B (x)	11.7	10.4	9.0	7.6	6.5	
EV/EBITDA (x)	58.3	48.9	40.8	30.3	25.4	
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	

Source: Company data, JM Financial. Note: Valuations as of 17/Nov/2025



Amey Chalke

amey.chalke@jmfl.com | Tel: (91 22) 66303056

Abin Benny

abin.benny@jmfl.com | Tel: (91 22) 69703621

We acknowledge the support of **Gourav Bhama** (gourav.bhama@jmfl.com) in preparation of this report.

### Recommendation and Price Target

Current Reco.	ADD
Previous Reco.	HOLD
Current Price Target (12M)	1,181
Upside/(Downside)	5.3%
Previous Price Target	1,112
Change	6.2%

### Key Data – MAXHEALT IN

Current Market Price	INR1,122
Market cap (bn)	INR1,090.5/US\$12.3
Free Float	72%
Shares in issue (mn)	971.9
Diluted share (mn)	971.9
3-mon avg daily val (mn)	INR4,159.0/US\$46.9
52-week range	1,314/936
Sensex/Nifty	84,951/26,013
INR/US\$	88.6

### Price Performance

%	1M	6M	12M
Absolute	-6.7	-3.9	11.5
Relative*	-7.8	-6.9	1.8

\* To the BSE Sensex


JM Financial Research is also available on: Bloomberg - JMFR <GO>, FactSet, LSEG and S&P Capital IQ.

Please see Appendix I at the end of this report for Important Disclosures and Disclaimers and Research Analyst Certification.

### ■ Financial highlight:

- Revenue at INR25.7bn (+21% YoY | +1/+1% vs street/JMFe)
- Gross Profit of INR 19.2bn (+19% YoY | in-line vs JMFe), with gross margin at 74.5% (-126bps YoY | -56bps vs JMFe)
- EBITDA at INR 6.9bn (+23% YoY | +2/+3% vs street/JMFe); EBITDA Margin at 26.7% (+28bps YoY | +16/+63bps vs street/JMFe)
- PAT at INR 5.6bn (+59% YoY | +37/+26% vs street/JMFe)
- 

### Exhibit 1. Valuation Chart (1Y FW EV/EB)



Source: Bloomberg

### Exhibit 2. 2QFY26 review

Max - P&L (INR mn)	2Q25A	2Q26A	% YoY	2Q26E	% Delta vs. JMFe	2Q26E (cons)	% Delta vs. cons	1Q26A	% QoQ
<b>Total Revenue</b>	<b>21,190</b>	<b>25,720</b>	<b>21%</b>	<b>25,500</b>	<b>1%</b>	<b>25,370</b>	<b>1%</b>	<b>24,510</b>	<b>5%</b>
COGS	5,130	6,550	28%	6,350	3%			6,310	4%
Gross Profit	16,060	19,170	19%	19,150	0%			18,200	5%
Gross Profit %	75.8%	74.5%	-126 bp	75.1%	-56 bp			74.3%	28 bp
Other Overheads	10,460	12,300	18%	12,500	-2%			12,150	1%
<b>EBITDA</b>	<b>5,600</b>	<b>6,870</b>	<b>23%</b>	<b>6,650</b>	<b>3%</b>	<b>6,735</b>	<b>2%</b>	<b>6,050</b>	<b>14%</b>
<b>EBITDA margin (%)</b>	<b>26.4%</b>	<b>26.7%</b>	<b>28 bp</b>	<b>26.1%</b>	<b>63 bp</b>	<b>26.5%</b>	<b>16 bp</b>	<b>24.7%</b>	<b>203 bp</b>
Finance cost/(Other Income)	50	410	720%	120				340	21%
Depreciation	970	1,220	26%	1,140				1,170	4%
<b>PBT</b>	<b>4,440</b>	<b>5,140</b>	<b>16%</b>	<b>5,590</b>	<b>-8%</b>			<b>4,400</b>	<b>17%</b>
Exceptional Items	200	180		0				220	
Tax	950	-410	-413%	1,200				960	-143%
Tax Rate (%)	20.5%	-7.7%		21.5%				20.8%	
Minority Interest									
<b>PAT (Reported)</b>	<b>3,490</b>	<b>5,550</b>	<b>59%</b>	<b>4,390</b>	<b>26%</b>	<b>4,062</b>	<b>37%</b>	<b>3,440</b>	<b>61%</b>
PAT margin (%)	16.5%	21.6%		17.2%		16.0%		14.0%	
Max - Cost margins	1Q25A	1Q26A	% YoY	1Q26A	% Delta vs. JMFe			1Q26A	% QoQ
COGS/sales	24.2%	25.5%	126 bp	24.9%	56 bp			25.7%	-28 bp
Staff cost/sales	49.4%	47.8%	-154 bp	49.0%	-120 bp			49.6%	-175 bp

Source: Company

## Financial Tables (Consolidated)

Income Statement						Balance Sheet					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E	Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Sales	68,150	86,210	1,03,611	1,34,637	1,60,286	Shareholders' Fund	92,950	1,05,330	1,21,410	1,43,231	1,67,807
Sales Growth	16.0%	26.5%	20.2%	29.9%	19.1%	Share Capital	0	0	0	0	0
Other Operating Income	0	0	0	0	0	Reserves & Surplus	92,950	1,05,330	1,21,410	1,43,231	1,67,807
<b>Total Revenue</b>	<b>68,150</b>	<b>86,210</b>	<b>1,03,611</b>	<b>1,34,637</b>	<b>1,60,286</b>	Preference Share Capital	0	0	0	0	0
Cost of Goods Sold/Op. Exp	16,350	21,150	26,214	32,986	39,591	Minority Interest	0	0	0	0	0
Personnel Cost	13,690	13,500	20,722	27,601	32,859	Total Loans	14,370	31,240	30,777	28,368	26,017
Other Expenses	19,380	28,830	29,529	37,968	45,521	Def. Tax Liab. / Assets (-)	370	1,510	1,510	1,510	1,510
<b>EBITDA</b>	<b>18,730</b>	<b>22,730</b>	<b>27,146</b>	<b>36,083</b>	<b>42,315</b>	<b>Total - Equity &amp; Liab.</b>	<b>1,07,690</b>	<b>1,38,080</b>	<b>1,53,697</b>	<b>1,73,108</b>	<b>1,95,335</b>
EBITDA Margin	27.5%	26.4%	26.2%	26.8%	26.4%	Net Fixed Assets	1,01,890	1,37,260	1,49,821	1,59,752	1,69,433
EBITDA Growth	16.6%	21.4%	19.4%	32.9%	17.3%	Gross Fixed Assets	0	0	0	0	0
Depn. & Amort.	2,840	4,060	4,939	5,069	5,320	Intangible Assets	0	0	0	0	0
EBIT	15,890	18,670	22,207	31,014	36,995	Less: Depn. & Amort.	0	0	0	0	0
Other Income	350	450	400	1,000	1,500	Capital WIP	0	0	0	0	0
Finance Cost	-380	840	1,650	1,700	1,700	Investments	660	40	40	40	40
PBT before Excep. & Forex	16,620	18,280	20,957	30,314	36,795	Current Assets	19,920	20,020	26,002	40,839	57,871
Excep. & Forex Inc./Loss(-)	-670	-1,540	-400	0	0	Inventories	1,060	1,340	1,703	2,213	2,635
PBT	15,950	16,740	20,557	30,314	36,795	Sundry Debtors	6,000	8,570	9,935	12,910	15,370
Taxes	3,160	3,390	2,878	6,063	7,359	Cash & Bank Balances	12,860	10,110	14,363	25,716	39,866
Extraordinary Inc./Loss(-)	-2,440	0	-1,228	-344	0	Loans & Advances	0	0	0	0	0
Assoc. Profit/Min. Int.(-)	0	0	0	0	0	Other Current Assets	0	0	0	0	0
Reported Net Profit	10,350	13,350	16,451	23,907	29,436	Current Liab. & Prov.	14,780	19,240	22,166	27,523	32,009
<b>Adjusted Net Profit</b>	<b>12,790</b>	<b>14,578</b>	<b>18,023</b>	<b>24,251</b>	<b>29,436</b>	Current Liabilities	4,610	4,890	5,135	5,391	5,661
Net Margin	18.8%	16.9%	17.4%	18.0%	18.4%	Provisions & Others	10,170	14,350	17,032	22,132	26,348
Diluted Share Cap. (mn)	971.9	971.9	971.9	971.9	971.9	Net Current Assets	5,140	780	3,835	13,316	25,862
<b>Diluted EPS (INR)</b>	<b>13.2</b>	<b>15.0</b>	<b>18.5</b>	<b>25.0</b>	<b>30.3</b>	<b>Total - Assets</b>	<b>1,07,690</b>	<b>1,38,080</b>	<b>1,53,697</b>	<b>1,73,108</b>	<b>1,95,335</b>
Diluted EPS Growth	17.6%	14.0%	23.6%	34.6%	21.4%						
Total Dividend + Tax	0	0	0	0	0						
Dividend Per Share (INR)	0.0	0.0	0.0	0.0	0.0						

Source: Company, JM Financial

Cash Flow Statement						Dupont Analysis					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E	Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Profit before Tax	15,950	16,740	20,557	30,314	36,795	Net Margin	18.8%	16.9%	17.4%	18.0%	18.4%
Depn. & Amort.	2,840	4,060	4,939	5,069	5,320	Asset Turnover (x)	0.7	0.7	0.7	0.8	0.8
Net Interest Exp. / Inc. (-)	-730	390	1,250	700	200	Leverage Factor (x)	1.2	1.3	1.3	1.3	1.2
Inc (-) / Dec in WCap.	810	1,610	1,198	1,872	1,605	RoE	14.7%	14.7%	15.9%	18.3%	18.9%
Others	1,540	2,680	400	0	0						
Taxes Paid	-3,160	-3,390	-2,878	-6,063	-7,359						
<b>Operating Cash Flow</b>	<b>17,250</b>	<b>22,090</b>	<b>25,466</b>	<b>31,892</b>	<b>36,561</b>						
Capex	-23,580	-39,430	-17,500	-15,000	-15,001						
<b>Free Cash Flow</b>	<b>-6,330</b>	<b>-17,340</b>	<b>7,966</b>	<b>16,892</b>	<b>21,560</b>						
Inc (-) / Dec in Investments	-640	0	0	0	0						
Others	-520	1,070	400	1,000	1,500						
<b>Investing Cash Flow</b>	<b>-24,740</b>	<b>-38,360</b>	<b>-17,100</b>	<b>-14,000</b>	<b>-13,501</b>						
Inc / Dec (-) in Capital	0	0	0	0	0						
Dividend + Tax thereon	-970	-1,458	-1,944	-2,430	-2,431						
Inc / Dec (-) in Loans	5,290	6,790	-10,463	-12,409	-12,350						
Others	380	-840	-1,650	-1,700	-1,700						
<b>Financing Cash Flow</b>	<b>4,700</b>	<b>4,492</b>	<b>-14,057</b>	<b>-16,539</b>	<b>-16,481</b>						
Inc / Dec (-) in Cash	<b>-2,790</b>	<b>-11,778</b>	<b>-5,691</b>	<b>1,353</b>	<b>6,579</b>						
Opening Cash Balance	15,650	12,860	10,110	14,363	25,716						
Closing Cash Balance	12,860	1,082	4,419	15,716	32,295						

Source: Company, JM Financial

## History of Recommendation and Target Price

## Recommendation History

Date	Recommendation	Target Price	% Chg.
13-Jul-24	Hold	840	
2-Aug-24	Hold	840	0.0
7-Nov-24	Hold	975	16.1
3-Feb-25	Hold	985	1.0
21-May-25	Hold	1,090	10.7
14-Aug-25	Hold	1,112	2.0

## Max Healthcare Institute



## APPENDIX I

### JM Financial Institutional Securities Limited

Corporate Identity Number: U67100MH2017PLC296081

Member of BSE Ltd. and National Stock Exchange of India Ltd.

SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst - INH000000610

Registered Office: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India.

Board: +91 22 6630 3030 | Fax: +91 22 6630 3488 | Email: [jmfinancial.research@jmfl.com](mailto:jmfinancial.research@jmfl.com) | [www.jmfl.com](http://www.jmfl.com)

Compliance Officer: Ms. Ashley Johnson | Tel: +91 22 6224 1862 | Email: [ashley.johnson@jmfl.com](mailto:ashley.johnson@jmfl.com)

Grievance Officer: Ms. Ashley Johnson | Tel: +91 22 6224 1862 | Email: [instcompliance@jmfl.com](mailto:instcompliance@jmfl.com)

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

New Rating System: Definition of ratings	
Rating	Meaning
BUY	Expected return >= 15% over the next twelve months.
ADD	Expected return >= 5% and < 15% over the next twelve months.
REDUCE	Expected return >= -10% and < 5% over the next twelve months.
SELL	Expected return < -10% over the next twelve months.

Note: For REITs (Real Estate Investment Trust) and InvIT (Infrastructure Investment Trust) total expected returns include dividends or DPU (distribution per unit)

Previous Rating System: Definition of ratings	
Rating	Meaning
BUY	Total expected returns of more than 10% for stocks with market capitalisation in excess of INR 200 billion and REITs* and more than 15% for all other stocks, over the next twelve months. Total expected return includes dividend yields.
HOLD	Price expected to move in the range of 10% downside to 10% upside from the current market price for stocks with market capitalisation in excess of INR 200 billion and REITs* and in the range of 10% downside to 15% upside from the current market price for all other stocks, over the next twelve months.
SELL	Price expected to move downwards by more than 10% from the current market price over the next twelve months.

\* REITs refers to Real Estate Investment Trusts.

#### Research Analyst(s) Certification

The Research Analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that:

All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and

No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

#### Important Disclosures

This research report has been prepared by JM Financial Institutional Securities Limited (JM Financial Institutional Securities) to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its associates solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of JM Financial Institutional Securities. This report has been prepared independent of the companies covered herein.

JM Financial Institutional Securities is registered with the Securities and Exchange Board of India (SEBI) as a Research Analyst and a Stock Broker having trading memberships of the BSE Ltd. (BSE) and National Stock Exchange of India Ltd. (NSE). No material disciplinary action has been taken by SEBI against JM Financial Institutional Securities in the past two financial years which may impact the investment decision making of the investor. Registration granted by SEBI and certification from the National Institute of Securities Market (NISM) in no way guarantee performance of JM Financial Institutional Securities or provide any assurance of returns to investors.

JM Financial Institutional Securities renders stock broking services primarily to institutional investors and provides the research services to its institutional clients/investors. JM Financial Institutional Securities and its associates are part of a multi-service, integrated investment banking, investment management, brokerage and financing group. JM Financial Institutional Securities and/or its associates might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, broking, financing or any other advisory services to the company(ies) covered herein. JM Financial Institutional Securities and/or its associates might have received during the past twelve months or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services.

JM Financial Institutional Securities and/or its associates, their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) covered under this report or (c) act as an advisor or lender/borrower to, or may have any financial interest in, such company(ies) or (d) considering the nature of business/activities that JM Financial Institutional Securities is engaged in, it may have potential conflict of interest at the time of publication of this report on the subject company(ies).

Neither JM Financial Institutional Securities nor its associates or the Research Analyst(s) named in this report or his/her relatives individually own one per cent or more securities of the company(ies) covered under this report, at the relevant date as specified in the SEBI (Research Analysts) Regulations, 2014.

The Research Analyst(s) principally responsible for the preparation of this research report and their immediate relatives are prohibited from buying or selling debt or equity securities, including but not limited to any option, right, warrant, future, long or short position issued by company(ies) covered under this report. The Research Analyst(s) principally responsible for the preparation of this research report or their immediate relatives (as defined under SEBI (Research Analysts) Regulations, 2014); (a) do not have any financial interest in the company(ies) covered under this report or (b) did not receive any compensation from the company(ies) covered under this report, or from any third party, in connection with this report or (c) do not have any other material conflict of interest at the time of publication of this report. Research Analyst(s) are not serving as an officer, director or employee of the company(ies) covered under this report.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and JM Financial Institutional Securities does not warrant its accuracy or completeness. JM Financial Institutional Securities may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision.

This research report is based on the fundamental research/analysis conducted by the Research Analyst(s) named herein. Accordingly, this report has been prepared by studying/focusing on the fundamentals of the company(ies) covered in this report and other macro-economic factors. JM Financial Institutional Securities may have also issued or may issue, research reports and/or recommendations based on the technical/quantitative analysis of the company(ies) covered in this report by studying and using charts of the stock's price movement, trading volume and/or other volatility parameters. As a result, the views/recommendations expressed in such technical research reports could be inconsistent or even contrary to the views contained in this report.

The investment discussed or views expressed or recommendations/opinions given herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and JM Financial Institutional Securities reserves the right to make modifications and alterations to this statement as they may deem fit from time to time.

This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction.

This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject JM Financial Institutional Securities and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions. Please click [here](#) to access our detailed Terms and Conditions, including the Most Important Terms and Conditions.

**Additional disclosure only for U.S. persons:** JM Financial Institutional Securities has entered into an agreement with JM Financial Securities, Inc. ("JM Financial Securities"), a U.S. registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") in order to conduct certain business in the United States in reliance on the exemption from U.S. broker-dealer registration provided by Rule 15a-6, promulgated under the U.S. Securities Exchange Act of 1934 (the "Exchange Act"), as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission ("SEC") (together "Rule 15a-6").

This research report is distributed in the United States by JM Financial Securities in compliance with Rule 15a-6, and as a "third party research report" for purposes of FINRA Rule 2241. In compliance with Rule 15a-6(a)(3) this research report is distributed only to "major U.S. institutional investors" as defined in Rule 15a-6 and is not intended for use by any person or entity that is not a major U.S. institutional investor. If you have received a copy of this research report and are not a major U.S. institutional investor, you are instructed not to read, rely on, or reproduce the contents hereof, and to destroy this research or return it to JM Financial Institutional Securities or to JM Financial Securities.

This research report is a product of JM Financial Institutional Securities, which is the employer of the research analyst(s) solely responsible for its content. The research analyst(s) preparing this research report is/are resident outside the United States and are not associated persons or employees of any U.S. registered broker-dealer. Therefore, the analyst(s) are not subject to supervision by a U.S. broker-dealer, or otherwise required to satisfy the regulatory licensing requirements of FINRA and may not be subject to the Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Any U.S. person who is recipient of this report that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, must contact, and deal directly through a U.S. registered representative affiliated with a broker-dealer registered with the SEC and a member of FINRA. In the U.S., JM Financial Institutional Securities has an affiliate, JM Financial Securities, Inc. located at 1325 Avenue of the Americas, 27th Floor, Office No. 2715, New York, New York 10019. Telephone +1 (332) 900 4958 which is registered with the SEC and is a member of FINRA and SIPC.

**Additional disclosure only for U.K. persons:** Neither JM Financial Institutional Securities nor any of its affiliates is authorised in the United Kingdom (U.K.) by the Financial Conduct Authority. As a result, this report is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the matters to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons.

**Additional disclosure only for Canadian persons:** This report is not, and under no circumstances is to be construed as, an advertisement or a public offering of the securities described herein in Canada or any province or territory thereof. Under no circumstances is this report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the registration requirement in the relevant province or territory of Canada in which such offer or sale is made. This report is not, and under no circumstances is it to be construed as, a prospectus or an offering memorandum. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. If you are located in Canada, this report has been made available to you based on your representation that you are an "accredited investor" as such term is defined in National Instrument 45-106 Prospectus Exemptions and a "permitted client" as such term is defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada nor should it be construed as being tailored to the needs of the recipient. Canadian recipients are advised that JM Financial Securities, Inc., JM Financial Institutional Securities Limited, their affiliates and authorized agents are not responsible for, nor do they accept, any liability whatsoever for any direct or consequential loss arising from any use of this research report or the information contained herein.